Managing Chronic Disease in Direct Primary Care (Diabetes, Hypertension and What the Evidence Shows)

How do you manage chronic disease in a direct primary care practice?

You manage it to the same standards as any primary care practice, using the American Diabetes Association and AHA/ACC guidelines, and you use the membership to make follow-up easier between visits. Because a message or a short check-in does not need a billable visit, a DPC practice can follow a patient more closely while a treatment is being adjusted. The evidence for that approach comes from general primary care research, because we found no controlled study of A1C or blood pressure control inside DPC practices. Time with each patient only helps if someone can also see who is overdue, so we suggest keeping a list of open care gaps from the first day.

This guide is written for physicians and owners deciding how to build this work into a practice. It is not medical advice for patients, and it is not legal advice. Every clinical threshold below links to the body that sets it and reflects that source as of our November 5, 2026 check, so please confirm against the current edition before you build a protocol on it.

What do the ADA and AHA/ACC standards recommend?

The American Diabetes Association publishes its Standards of Care in Diabetes in yearly editions, along with an abridged version for primary care professionals that is free to read. The table below pulls the intervals that most directly shape a practice's workflow from the 2026 edition. These are population starting points, and the ADA says goals should be individualized by factors such as duration of diabetes, age, life expectancy, comorbid conditions and hypoglycemia awareness.

For hypertension, the governing document is the 2025 AHA/ACC multisociety guideline, and the JACC Guideline-at-a-Glance is the shortest accurate summary we found. It sets an overarching treatment goal below 130/80 mm Hg for all adults, with additional considerations for those who require institutional care, have a limited predicted lifespan or are pregnant. Stage 1 is 130 to 139 systolic or 80 to 89 diastolic, and stage 2 is 140 or higher systolic or 90 or higher diastolic.

The summary recommends medication alongside lifestyle changes for all adults averaging 140/90 mm Hg or higher, and for selected adults at 130/80 or higher who have clinical cardiovascular disease, previous stroke, diabetes, chronic kidney disease or a 10-year PREVENT risk of 7.5% or more. Adults at lower risk get a 3 to 6 month trial of lifestyle change first. For stage 2, it prefers starting two first-line drug classes in a single-pill combination over two separate pills. The full guideline also says to check a basic metabolic panel 2 to 4 weeks after starting or adjusting specific classes, including diuretics, ACE inhibitors and ARBs, which is the kind of date that benefits from a task instead of a good memory.

Does longer access actually improve diabetes and blood pressure control?

The closest evidence is about encounter frequency, and it comes from outside DPC. A retrospective cohort of 26,496 patients with diabetes, treated by primary care physicians at two teaching hospitals between 2000 and 2009, compared encounters every 1 to 2 weeks with encounters every 3 to 6 months. Median time to an A1C below 7.0% was 4.4 versus 24.9 months for patients not on insulin. Median time to a blood pressure below 130/85 mm Hg was 1.3 versus 13.9 months. The authors counted an encounter as a note in the medical record, and they tied the fastest control to encounters about every 2 weeks.

That study is an association from two teaching hospitals, so it cannot prove that more contact caused the difference. It is still useful to a DPC owner, because it describes a follow-up pattern a membership can pay for. One way to apply it is closer contact during titration and a return to the ADA's longer interval once the patient is at goal.

Team-based care has stronger support. The Community Preventive Services Task Force recommends it after a review of 54 studies, reporting that the share of patients with controlled blood pressure rose by a median of 8.5 percentage points (39 studies) and systolic pressure fell by a median of 3.5 mm Hg (44 studies). The team in those studies adds staff or changes existing roles and includes professionals such as nurses, pharmacists, dietitians, social workers and community health workers, which is not the same as a medical assistant, and the AAFP's 2026 DPC data brief reports that 69% of DPC practices ran a single physician panel. If that describes you, the useful question is which parts of titration follow-up can move to a trained medical assistant under your protocol and your state's scope rules.

How do visit length and panel size affect chronic care?

Here the research describes the constraint better than it describes DPC. A 2005 study in Annals of Family Medicine estimated that guideline care for 10 common chronic diseases on a panel of 2,500 would take 3.5 physician hours a day if every condition were stable, and 10.6 hours once time for uncontrolled disease was factored in. A 2023 update in the Journal of General Internal Medicine estimated 26.7 hours a day for all recommended adult primary care on the same panel size, of which 7.2 hours was chronic disease care, and 9.3 hours a day with team-based care.

Those are models, and they assume an average population, adults only in the 2023 paper. As a rough guide of our own, not a finding from either paper, scaling the 2023 estimate down in a straight line to the average panel of 504 that the AAFP reports across all its survey respondents, 53% of them in DPC, gives an estimate of about 5.4 hours a day for all recommended care, of which about 1.5 hours would be chronic care. A panel with more diabetes than average would need more than that, and DPC panels include children, whom the 2023 model leaves out. A 2012 model that delegated part of preventive and chronic work estimated that a team could carry 1,387 to 1,947 patients, which is a reminder that delegation moves this number as much as panel size does.

On what DPC practices actually do, the best recent source is self-reported. The AAFP 2026 data brief surveyed family physicians who had engaged with DPC content, with 313 respondents at a 9.3% response rate, 167 of them practicing in a DPC setting. Across all 313 respondents, not only those in DPC, it reports an average panel of 504 in 2025 and 40 patient encounters a week. It also reports 13 e-visits a week without naming the group. Among those practicing in DPC, 54% reported an average in-office appointment longer than 30 minutes and 4% reported under 15 minutes. It does not report chronic disease mix, so we cannot tell you how those numbers change for a panel heavy in diabetes, and we found no source that does.

Whether longer visits improve chronic disease outcomes is less settled. A JAMA Health Forum study of 8.1 million visits in 2017 found that each added minute was associated with a 0.11 percentage point lower chance of an inappropriate antibiotic for an upper respiratory infection, along with a smaller drop in opioid and benzodiazepine coprescribing. It is cross-sectional and measures prescribing, not A1C or blood pressure.

What do studies of DPC show, and what do they not show?

They show lower use of some services for one employer's members, and they do not show better chronic disease control. A vendor report cites a 2018 comparison of one DPC network's members against PPO rates on A1C and blood pressure control, with no stated adjustment for who enrolls, so we don't count it as a controlled study. People who choose a membership may also differ from those who do not.

The Milliman report also found the DPC group's risk score 8.3% lower than the comparison group's, and it noted preliminary evidence that employer-arranged DPC tends to attract healthier patients. For anyone claiming a chronic disease benefit, that is the question to answer first. We also ran a PubMed title and abstract search on November 5, 2026 for "direct primary care" with diabetes, hypertension, A1C or "chronic disease" in the title or abstract. It returned two records, and going by the titles, the only one about DPC as a model was a 2021 article on its financial structure for lifestyle medicine. A narrow search can miss work, so please tell us if you know of a controlled study. For the wider research, see is direct primary care worth it.

How do in-house labs and generics fit into chronic care?

They shorten the loop between a result and a decision, and the ADA gives a clear reason to care about cost. Its Section 9 says to routinely assess all people with diabetes for financial obstacles (Rec. 9.29), and it says that for adults with cost-related barriers, lower-cost options such as metformin, sulfonylureas, thiazolidinediones and human insulin can be considered within the context of their risks (Rec. 9.30). Those risks include hypoglycemia, weight gain, and cardiovascular and kidney events, so a lower price does not settle the choice. Building the question into the visit template makes sure it gets asked.

The AAFP's 2026 data brief reports that 54% of DPC practices dispensed noncontrolled medications in-house, down from 63% in 2024. Whether you can dispense depends on your state, and our guide to dispensing medications and labs covers state rules, DEA registration and CLIA. The HSA rules also matter here, since they affect what can sit inside the membership fee.

For point-of-care testing, a practice running only waived tests must follow the manufacturer's instructions and meet the certificate of waiver requirements. The ADA adds a useful caution in Section 6, noting that point-of-care A1C offers timely chances to adjust treatment during a visit, although point-of-care tests may be less accurate than laboratory assays. Decide in advance when an in-office result is enough and when you want the lab's confirmation.

How does remote monitoring work in a membership?

Home blood pressure has the firmest footing. The Guideline-at-a-Glance calls home monitoring, combined with frequent team interactions and standardized protocols, an important tool for improving control, and it says to avoid relying on cuffless devices, including smartwatches, until they show greater precision and reliability. The full guideline describes only modest reductions from home monitoring alone in meta-analyses, and stronger support when it is paired with education, telehealth and titration using prespecified algorithms. The ADA's Rec. 10.2 says to counsel all people with hypertension and diabetes to monitor at home after appropriate education.

A reading helps when someone reviews it on a set schedule and has a rule for what happens next. Our guide to remote patient monitoring for DPC covers devices, continuous glucose monitors, how readings reach the clinic and HIPAA. If you have opted out of Medicare, as covered in our opt-out guide, 42 CFR 405.425 bars you from submitting Medicare claims for this work, so it becomes part of what the membership provides. Before you start, decide who looks at readings, how often, and what happens when that person is away.

How do you track care gaps in a small practice?

Build one list from the intervals above, and let it show who is overdue without anyone having to remember. We did not find a national benchmark for DPC practices, so your own baseline is the comparison that counts. The table below is enough for a first version, and it can live in your EHR's reporting tools or a tracker that meets your HIPAA obligations.

The eye exam needs extra care, because it happens elsewhere and the result has to come back. That is the same problem as any referral, and our specialist referral tracking workflow and guide to specialist access in DPC both apply. The chronic care management task tracking guide describes why standing monthly lists slip even with diligent staff, and that part holds whether or not you ever bill for the work.

If an employer contract asks for data, or you simply want an outside yardstick, CMS publishes two measure definitions you can borrow. CMS122 counts patients 18 to 75 with diabetes whose most recent glycemic status is above 9.0%, or is missing or was not done during the measurement period, and lower is better. CMS165 counts patients 18 to 85 with essential hypertension whose most recent blood pressure was below 140/90 mm Hg, and higher is better. Those are reporting measures and are looser than the clinical goals above, so treat them as a floor. The metrics guide covers the business numbers to track beside them.

Why is this list so hard to keep in a small practice?

We put that down to the tools. A lab result can land in one system, a home reading in a text thread and an eye report in a fax inbox, because those systems were never built to talk to each other. What is missing is one place that shows the whole panel at once.

That is the work Tabflows does as a dedicated tech team, connecting the EHR, billing and messaging tools a clinic already uses so that follow-ups, tasks and patient context sit in one place. Whichever way you solve it, here is a test you can run this week. Pick your patients with diabetes, ask who is overdue for kidney testing, and see how long it takes to get an answer you trust.